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Abstract
Background: Rare mutations of the low-density lipoprotein receptor gene (LDLR) cause familial hypercholesterolemia, which
increases the risk for coronary artery disease (CAD). Less is known about the implications of common genetic variation in the
LDLR gene regarding the variability of cholesterol levels and risk of CAD.
Methods: Imputed genotype data at the LDLR locus on 1 644 individuals of a population-based sample were explored for
association with LDL-C level. Replication of association with LDL-C level was sought for the most significant single
nucleotide polymorphism (SNP) within the LDLR gene in three European samples comprising 6 642 adults and 533 children.
Association of this SNP with CAD was examined in six case-control studies involving more than 15 000 individuals.
Findings: Each copy of the minor T allele of SNP rs2228671 within LDLR (frequency 11%) was related to a decrease of LDL-C
levels by 0.19 mmol/L (95% confidence interval (CI) [0.13–0.24] mmol/L, p=1.5610
210). This association with LDL-C was
uniformly found in children, men, and women of all samples studied. In parallel, the T allele of rs2228671 was associated
with a significantly lower risk of CAD (Odds Ratio per copy of the T allele: 0.82, 95% CI [0.76–0.89], p=2.1610
27).
Adjustment for LDL-C levels by logistic regression or Mendelian Randomisation models abolished the significant association
between rs2228671 with CAD completely, indicating a functional link between the genetic variant at the LDLR gene locus,
change in LDL-C and risk of CAD.
Conclusion: A common variant at the LDLR gene locus affects LDL-C levels and, thereby, the risk for CAD.
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Introduction
A causal link between serum cholesterol levels and coronary
artery disease (CAD) risk is supported by multiple epidemiological
association studies as well as treatment trials involving lipid-
lowering drugs[1]. Less clear are the implications of acquired
versus heritable variability of low-density lipoprotein cholesterol
(LDL-C) levels as the latter may come into effect already during
childhood[2]. Some insights in this respect come from relatively
rare mutations either decreasing or increasing LDL-C levels. For
example, a variant in the PCSK9 gene has been associated with a
substantial decrease in serum LDL-C levels and almost abolished
myocardial infarction (MI) risk[3]. Similarly, rare mutations in the
LDL-receptor gene (LDLR) are known to cause familial hyper-
cholesterolemia (FH), a condition which is characterized by
markedly increased LDL-C levels resulting in premature manifes-
tation of atherosclerotic disease[4]. More recently, several genome
wide association studies on lipid traits have identified common
SNPs located in the LDLR gene locus showing significant
association with LDL-C levels[5,6,7]. The study by Willer and
coworkers has also presented suggestive evidence for the
association of SNP rs6517720 with CAD on one population [6].
This SNP shows high linkage disequilibrium with SNP rs2228671
for which the association with LDL-C and CAD is investigated in
detail and across multiple populations in the study presented here.
Inheritance of either relatively low or high LDL-C levels may be
interpreted as a Mendelian Randomisation study, which allows to
specifically analyse the genetic component in the variability of this
risk factor[8,9]. Particularly, such studies offer the opportunity to
test a potentially causal association between risk factor and disease
given that interference of behavioural, social, and environmental
factors, that otherwise may confound the relationship, is largely
excluded by ‘‘Randomisation to the genetic variant’’. Here, we
attempted to identify more frequent genetic variants affecting
LDL-C levels and thereby to further study the relation between




Initially, the LDLR genomic region was screened in 1644
population-based subjects of the KORA F3 study for association
with LDL levels using genotype data obtained with the GeneChipH
Human Mapping 500K Array (Affymetrix, ) enriched by imputed
genotypes based on the genome-wide dataset. The single nucleotide
polymorphism (SNP) at the LDLR gene locus showing the strongest
association with LDL-C levels was further investigated. Particularly,
association with LDL-C was examined in several population-based
studies comprising adults and children, and association with
coronary artery disease (CAD) was tested in six case-control studies.
Figure 1 a and 1b provide an overview of the experimental strategy
and study populations involved. Details on each of the study
populations are provided in the supplementary methods (Methods
S1 and table S1). Briefly, the MONICA/KORA F3 and S4 studies
aswellas thePopGenpopulation controlsrepresent individualsfrom
strictly age- and gender-stratified surveys of the German popula-
tion[10,11,12,13]. A total of 533 overweight but otherwise healthy
children and adolescents (mean age 10.863.1 years) came from the
West German Obesity Cohort of the Bonn/Datteln Childhood
Obesity Study Group [14].
To investigate the association of SNP rs2228671 with CAD we
performed genotyping of this SNP in four case-control studies
(German MI Family Study II[15], PopGen CAD cases[12], Left
Main Disease Study[16], Aachen Heart Study[17]) and imputed
genotypes for this SNP in two further studies for which genome-wide
association data were available (German MI Family Study I,
WTCCCCADstudy)[18].ControlsubjectsfromtheKORAF3and
S4 samples were matched to cases for the German MI Family study
1, Left-main disease and Aachen Heart studies. The matching
procedure ensured that a control subject was used only once in any
ofthesethreesamples.NoLDL-valueswereavailableforthesubjects
of the Aachen, WTCCC and Left-main disease studies. All samples
have been established in accordance with the principles of the
Declaration of Helsinki and were approved by the respective local
ethics committees. Laboratory measurements of LDL-C in non-
fasting individuals were performed after precipitation of apolipo-
protein-B containing lipoproteins and measured with standard
enzymatic methods. Gene arrays in the MONICA/KORA F3
survey, the WTCCC CAD study and the German MI Family Study
I were performed with the Affymetrix GeneChipH 500K Mapping
Array Set as previously described in detail[18]. For the MONICA/
KORA S4, PopGen, German MI Family Study II studies and West
German Obesity Cohort genotyping for rs2228671 was done using
59exonuclease activity (Taqman) assay on a HT7900 (Applied
Biosystems, Darmstadt, Germany). SNP-assays were ordered from
Applied Biosystems as Custom TaqManH SNP genotyping assay.
Statistical analysis
At the LDLR locus (Chromosome 19p13.2, base pair position
10.900.000 to 11.300.000 according to NCBI Build 36.1), we
investigated 33 genotyped and 223 imputed SNPs for association
with LDL-C levels. For assessing the effects of variants not
represented on the Affymetrix GeneChipH 500K Mapping Array
Set, haplotypes were estimated using the CEU sample from the
HapMap project (http://www.hapmap.org/)[19] and further
variants were imputed using MACH 1.0 (http://www.sph.
umich.edu/csg/abecasis/MACH/index.html). Association analy-
sis of LDL-C on SNPs adjusted for age and gender were
performed with MACH2QTL. SNPs with a predicted coefficient
of determination r
2,0.3 were excluded from the analyses.
Allele frequencies were analyzed in control populations by a x
2-
test.
For every study group individually, deviations of genotype
distribution from and compatibility with Hardy-Weinberg equi-
librium (HWE) were analyzed (details see supplement).
LDL-C was regressed on rs2228671 for each population-based
group and subjects of the West German Obesity Cohort
separately. A prospectively planned pooled analysis using
individual data as proposed by Blettner et al. [20] was performed
using all control groups studied by regressing LDL-C on
rs2228671 with study as random effect (details see supplement).
We additionally stratified the analysis by gender and age groups.
Means, standard errors, and p-values are reported.
The power for detecting an association between rs2228671 and
CAD was calculated using Quanto (http://hydra.usc.edu/GxE/)
assuming a log-additive model a=0.05 and power=80% (details
see supplement).
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between CAD cases and controls for every study using the two-sided
asymptotic Cochrane-Armitage trend test. Heterozygous and
homozygousoddsratios (OR) forthe minor alleleand corresponding
95% confidence intervals (CI) were estimated. In the prospectively
planned pooled analysis[20] we investigated the additive effect of
rs2228671 on CAD unadjusted and adjusted for LDL-C by random
effect logistic regression models. The most likely genetic model for
rs2228671 on serum LDL-C and for rs2228671 on CAD was
investigated using logistic regression models and the Minelli
approach[21] (details see supplement)[16,22] .
There was no adjustment for population stratification (details
see supplement).
The association of rs2228671 with serum LDL-C was utilized to
investigate the possible causal effect of serum LDL-C on CAD
(Mendelian Randomisation). The inheritance of rs2228671 should
be subject to the random assortment of parental alleles at the time
of gamete formation. If serum LDL-C increases the risk of CAD,
then carriage of an allele that exposes individuals to a long-term
elevation in serum LDL-C should confer an increased risk of CAD
proportional to the difference in serum LDL-C attributable to the
allele. This relationship is largely unconfounded and free of reverse
causality bias if specific assumptions are met [23,24,25,26,27] e.g.,
that rs2228671 is independent of CAD given serum LDL-C. To
investigate these relationships between LDL-C, CAD and
rs2228671, we fitted a structural equation model using data from
cases and controls with known non-use of lipid lowering agents or
estimated before-treatment LDL-C levels by correction of
measured values for the dosage of a given lipid lowering agent
according to a previously published algorithm [28]. In addition,
structural equation models including known confounders (age,
gender, smoking status, diabetes, and hypertension) were fitted. In
case of non-linear variables, the structural equation approach
allows a simple interpretation of the regression coefficients when
compared with an instrumental variable approach [5]. Estimation
was done using MPlus 5, which allows specification of categorical
variables, and sensitivity analyses were performed with SEPATH
using correlation coefficients estimated by use of the polychor
package within R. For this analysis, adjustments for population
stratification in the present studies are not required because only
Figure 1. Figure 1a: Strategy for exploring the association of LDLR polymorphism rs2228671 with LDL-C levels and CAD across multiple
populations. Studies based on imputed genotypes for rs2228671 are marked with a *. Figure 1b: Schematic overview of study populations
doi:10.1371/journal.pone.0002986.g001
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population heterogeneity is negligible in the German population as
previously demonstrated [Samani et al. 2007; Steffens et al. 2006].
Results
The genomic region of the LDLR located at 19p13.2 was
screened for association with LDL-C levels using data from a gene
array study performed in the MONICA/KORA F3 survey. Nine
of 33 SNPs representing the region on the Affymetrix GeneChipH
500K Mapping Array Set (black squares in Fig. 2a) showed
association with LDL-C levels with a p-value ,0.05 (see table S2).
A higher density of SNPs mapping to the LDLR genomic region
resulted from imputation of further SNPs, which predicted
genotypes for 223 additional SNPs located at 19p13.2. Of these,
185 passed quality analyses (blank circles in Fig. 2a; see Methods
section), and 50 were associated with LDL-C levels with a p-value
,0.05. Two of these SNPs showed markedly higher levels of
significance for association with LDL-C than the surrounding
SNPs: rs6511720 (predicted p-value=4.6610
26) and rs2228671
(predicted p-value=2.4610
26). The SNP with the strongest effect
(0.36 mmol/L mean difference per one T allele, 95% CI
[0.21,0.52] mmol/L; rs2228671; red circle in Fig. 2a) was chosen
for replication in further populations.
In order to verify the predicted association of the imputation
experiment we genotyped SNP rs2228671 using the 59-exonucle-
ase method in 1 644 subjects of the MONICA/KORA F3 study
demonstrating a slightly higher (3.6%) minor allele frequency than
in imputed genotypes. However, the relation between rs2228671
and LDL-C remained consistent for the genotyped SNP (Fig. 3a).
We then confirmed this association in the larger MONICA/
KORA S4 study comprising 4 184 individuals with a mean
difference per T allele of 0.20 mmol/L (95% CI [0.13–0.28]
mmol/L; p=2.6610
28) and the population-based PopGen study
comprising 2 458 individuals with a mean difference per T allele of
0.14 mmol/L (95% CI [0.06–0.23] mmol/L; p=0.0012; Fig. 3a).
In order to test if the association of rs2228671 with LDL-C was
already detectable before adulthood we performed additional
genotyping in children and adolescents referred for treatment of
obesity. In this sample we found a mean difference per T allele of
0.20 mmol/L (95% CI [0.03–0.37] mmol/L; p=0.0220; Fig. 3a).
The genetic effect of rs2228671 on LDL-C is most likely
additive (see Methods S1). This implies that individuals carrying a
copy of the T allele have a lifelong exposure to lower LDL-C levels
than homozygous C allele carriers with a reduction of 0.19 mmol/
L per T allele (95% CI [0.13–0.24] mmol/L; p=1.5610
212;
Fig. 3a). Furthermore, the genetic variant represented by SNP
rs2228671 affected LDL-C levels to a similar extent in men and
women and across different age groups (Fig. 3b).
Since carriers of the minor allele of SNP rs2228671 have a
lifetime of lower LDL-C levels we hypothesized that this translates
into a lower CAD risk. To explore this hypothesis, we performed
imputation of SNPs located at the LDLR gene locus in two
genome-wide association studies of the German MI Family I and
WTCCC CAD studies (Fig. 1). In both studies we observed a
significant association of the imputed T allele of rs2228671 with
CAD risk resulting, expectedly, in decreased ORs for disease
manifestation (Fig. 4). Additionally, the association of rs2228671
with CAD was explored by genotyping in four case-control studies
for CAD comprising a total number of 4 310 cases and 8 086
controls. Across all six studies, we found an association with CAD
with an OR per copy of the T allele of 0.82 (95 % CI [0.76–0.89],
p=2.1610
27, Fig. 4, for genotype distribution and p-values of
individual studies see Table S3).
According to the PROCAM-Algorithm[29] a reduction in
LDL-C of 0.38 mmol/L, as found in TT versus CC homozygous
individuals in the population-based studies translates into a 21%
reduction in the risk of cardiovascular events over a 10 year
period. In fact, reduction in risk of CAD by 23% was observed for
homozygosity of the minor allele of rs2228671 in the combined
analysis of all individuals.
In order to further examine whether a lower risk of CAD, as
observed in carriers of the T allele, is causally linked to the
genetically determined lower LDL-C associated with this common
SNP in the LDLR gene, we performed a Mendelian Randomisa-
tion study. For this analysis we focused on individuals on whom
native LDL-C levels, i.e., levels not a ffected by or corrected for
lipid lowering medication, were available or could be estimated (1
324 cases and 6 255 controls). The structural equation model
revealed a highly significant association between the genotype and
LDL-C as well as between LDL-C and CAD risk, but the
association between rs2228671 and the risk of CAD was abolished
(OR 0.99, 95 % CI [0.85–1.16], p=0.95, Fig. 5). Including known
confounders, which were found to be independent of rs2228671,
did not change the results (see Fig. S1). Further, these findings
were confirmed by regression analysis adjusting the CAD risk
related to rs2228671 for LDL-C (see Table S3). Thus, the
protective effect on CAD risk observed for the T allele is likely to
be causally linked to the reduction in LDL-C associated with this
particular variant in the LDLR gene (Fig. 5).
Discussion
We identified a common variant in the LDLR gene that is
related to lower LDL-C levels and a lower risk of CAD and MI. In
the PROCAM and Framingham risk scores, a decrease of LDL-C
by 0.38 mmol/L, as found in homozygote carriers of the T allele,
matches a 21–23% decrease of MI risk[29,30]. We observed an
effect of such magnitude in six consecutive samples with CAD
cases and healthy controls.
We replicated the association of rs2228671 with LDL-C levels
in individuals across a wide age spectrum including children.
Interestingly, the magnitude of difference in LDL-C levels was
stable in all subgroups studied suggesting a stepwise decrease of
lifetime exposure to lower cholesterol levels for each copy of the T
allele. In parallel, we observed a stepwise decrease in CAD risk.
Together with the data from the Mendelian Randomisation, the
findings plausibly suggest a functional link between the decrease in
cholesterol and the decrease in CAD risk related to the genetic
variant or a closely linked variant.
From a clinical point of view the variability in LDL-C modulated
by rs2228671 genotypes might be considered rather small in
comparison to the profound LDL-C lowering achieved in recent
therapeutic trials (examples: CARE[31]: D1.1 mmol/L, Heart
Protection Study[32]: D1.0 mmol/L,TNT[33]: D1.9 mmol/L
)[34]. Yet the risk reduction for CAD events reached almost the
same magnitude as observed by statin treatment in these trials[1].
Thus, it seems conceivable that a lifelong reduction of LDL-C by
0.38 mmol/L inhomozygotesfor theT ratherthan the C alleleorin
individuals followed long-term in epidemiological cohorts is
comparable to the effects of 3–5 years of statin treatment, which
byitselfresultsinmuchlargerLDL-Clowering.Inthisrespectitmay
be of inerest that the variability of LDL-C levels carries a high
heritability such that the effects observed in the population may
indeed reflect to a large extent the effects of underlying genetic
factors[35]. Previous studies using the Mendelian Randomization
approach have observed an even greater change in CAD risk
through lifelong genetic lowering of cholesterol than predicted by
SNP in LDLR and CAD Risk
PLoS ONE | www.plosone.org 4 August 2008 | Volume 3 | Issue 8 | e2986Figure 2. Figure 2a: Association of the chromosomal locus 19p13.2 with LDL-C levels in population-based sample. Presented are p-values from
linear regression of LDL-C on SNPs adjusted for age and gender. p-values of the SNPs genotyped on the Affymetrix GeneChipH 500K Mapping Array
Set are displayed as closed squares, p-values predicted by HapMap-based imputation are displayed as blank circles. SNP rs2228671 is highlighted as a
red circle. Figure 2b: Linkage disequilibrium structure of the genomic region surrounding SNP rs2228671. Displayed are the HapMap data (r
2;[19]) of
all SNPs surrounding rs2228671 (11030947–11079189) and the genes within this region.
doi:10.1371/journal.pone.0002986.g002
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PLoS ONE | www.plosone.org 5 August 2008 | Volume 3 | Issue 8 | e2986Figure 3. Figure 3a: Association of SNP rs2228671 with LDL-C levels across populations. Displayed are means of LDL-C and standard error of means
stratified by rs2228671 genotype. Unadjusted levels of significance are displayed for each individual study. Effects for the pooled study are from a
random effect linear regression model. Figure 3b: Pooled analysis of the association of rs2228671 with LDL-C across populations stratified by age
groups and gender. Displayed are means of LDL-C and standard error of means stratified by rs2228671 genotype, separately for age groups (,20, 21–
35, 36–50, .50), men and women.
doi:10.1371/journal.pone.0002986.g003
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PLoS ONE | www.plosone.org 6 August 2008 | Volume 3 | Issue 8 | e2986epidemiological scores [2,3]. However, the sample size of the rare
variants was small such that the conclusions of these previous studies
onPCSK9 arein line withourstudywiththeriskreductionobserved
for the protective allele being similar to the risk reduction predicted
by epidemiological scores.
Several genes are known to affect LDL-C and MI risk including
those coding for APOB[36,37], LDLR[38], and PCSK9[3].
However, until recently only variants with fairly low allele
frequencies ranging between 0.001 to 0.08% in the APOB gene
[36], 0.01 to 0.02% in the LDLR gene [39], and 2 to 3 % in the
PCSK9 gene had been identified [3]. With the availability of
GWAs based DNA-Arrays, a number of more frequent variants
affecting LDL-levels emerged [5,6,7,35,40]. Indeed, association of
rs2228671 with LDL-C can be found in the comprehensive data of
a GWA meta-analysis of three British populations comprising
4337 individuals[5]. Furthermore, the SNP has previously been
implicated with hyperlipidemia in interaction models and
haplotype analyses[41,42]. However, a direct association of this
SNP with LDL-C levels and CAD risk has not been demonstrated
so far. While it was unclear whether the T allele of the LDLR
polymorphism rs2228671 also affects coronary artery disease risk
the relatively high prevalence of the minor allele (frequency 11%)
made it plausible that the contribution of rs2228671 to the
variability of LDL-C serum levels also translates to a modification
in CAD risk at the population level.
In parallel to the present work, Kathiresan and coworkers
studied two polymorphisms from the LDLR locus (rs1529729 and
rs688) in a CAD prediction score that was based on genotypes that
had previously displayed association with lipid levels. Indeed, this
score allowed to predict cardiovascular events in a prospective
cohort [35]. However, both SNPs from the LDLR included in this
score are not in significant linkage disequilibrium with rs2228671
such that the present findings are likely to further extend the
implications of common genetic variation for prediction of LDL
variability and CAD risk.
Strengths of the present study include the utilisation of several
population-based samples and several cohort studies displaying
consistently significant effects across multiple sub-groups as well as
broad replication in multiple case-control studies. Moreover,
evidence for a causal link between modulation of LDL-C levels
and CAD risk is strongly supported by the Mendelian Randomisa-
tion approach. Nevertheless, limitations of the present work need
Figure 4. Association of rs2228671 with risk of CAD in six case-control studies. Displayed are heterozygous and homozygous ORs for CAD
and 95% CI per study from two-sided asymptotic Cochrane-Armitage trend test. Pooled ORs, 95% CIs and p-values are from random effect logistic
regression models. The number of individuals in each study is represented by size of the closed square. SNP rs2228671 was imputed from the
Affymetrix GeneChipH 500K Mapping Array Set in the WTCCC and German MI Family Study I and genotyped directly in the remaining studies.
doi:10.1371/journal.pone.0002986.g004
Figure 5. Results of Mendelian Randomisation study. Exploration
of the causal relationship between LDL-C associated with rs2228671
and CAD (Mendelian Randomisation). In the structural equation model,
carriage of the T allele at rs2228671 leads to lower LDL-C levels, and
higher LDL-C levels lead to an increased risk of CAD. Given this, there is
no additional direct path from rs2228671 to CAD risk, indicating that
the functional pathway between the genetic variant at the LDLR gene
locus and risk of CAD is through changes in LDL-C.
doi:10.1371/journal.pone.0002986.g005
SNP in LDLR and CAD Risk
PLoS ONE | www.plosone.org 7 August 2008 | Volume 3 | Issue 8 | e2986consideration including the fact that we cannot mechanistically
explain the decrease in LDL-C associated with the T-allele. SNP
rs228671 is located within the first exon of LDLR in the third
position of a triplet coding for amino acid 27, a cysteine (Fig. 2b).
However, allelic variation in this SNP does not result in an amino
acid change. No further polymorphisms in LDLR are known to
cause amino acid changes or previously associated with LDL-C
levels or CAD were found to be in linkage disequilibrium with
rs2228671 or rs6511720[6,7], suggesting that hitherto unknown
mechanisms are responsible for this association. Both, gain of
function or increased expression of the LDLR are possible to affect
LDL-C serum levels. Remotely, there is even a chance that
another gene in linkage disequilibrium with the variant accounts
for the observed effects.
Whatever the underlying molecular mechanism is, from a
genetic point of view this study on multiple populations offers
robust data that the rs2228671 T-allele goes along with lower
LDL-C levels and, secondary to this effect, a lower risk of CAD.
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